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Additive and synergistic effects of cyclosporine metabolites on glomer.
War mesangial cells. Out of the 29 cyclosporin (Cs) metabolites defined
so far, 10 representative ones were isolated from bile of liver grafted
patients, purified by HPLC, and their structure specified by FAB-MS
and 'H NMR. These were used to determine the growth inhibitory
effects on Sprague Dawley rat glomerular mesangial cells (MC). Me-
tabolite dilutions were added to cultured MC for 72 hours and [3H]-
thymidine incorporation was measured. A 50% growth inhibition by
single metabolites (M) on MC was achieved at the following concen-
trations (mg/liter): Cs: 1.25; M21: 6.0; M18: 9.0; M26: 10.5; Ml: 10.8;
M8: 10.8; M17: 12.5; M13: >20.0; M25: >25.0; M203-218: >50.0; H355:
>50.0. The activity was correlated to the degree of metabolization as
the group of six "active" compounds included four primary metabolites
(hydroxylated or demethylated derivatives of Cs: M21, M18, Ml, M17),
whereas the four "inactive" compounds exclusively were secondary
metabolites (demethylated, hydroxylated and/or oxidized primary
metabolites: Ml3, M25, M203-218, H355). Combinations of active
metabolites with or without Cs resulted in an additive antiproliferative
effect. Although single metabolite activities are not relevant in vivo,
already combinations of three (Ml + M17 + M18) or four metabolites
(M17 + Ml8 + M21 + H355) resulted in a significant growth inhibition
at concentrations of the participating metabolites measured in urine of
liver transplanted patients. Moreover, significant synergistic activities
were determined with combinations including secondary metabolites. A
final set of experiments discharged unspecific cytotoxic effects. The
inhibition of MC [3H}-thymidine incorporation was completely revers-
ible and moreover, direct mesangiolysis was excluded for both single
and combined metabolite actions. Thus, considering rat MC prolifera-
tion as an initial kidney cell model system for subsequent, more detailed
studies measuring functional parameters, we have demonstrated that
activities of single metabolites are related to their chemical structure.
More importantly, mimicking to some extent the patients' situation,
combinations of metabolites at concentrations occurring in vivo re-
duced MC proliferation in culture in an at least an additive fashion,
suggesting that side effects of Cs treatment might be attributed to
combined Cs metabolite actions.
The abundant use of the immunosuppressive drug cyclospo-
rine (Cs) in transplantation and increasingly in the treatment of
several autoimmune diseases [1—3] makes studies trying to
elucidate the mechanisms of toxic effects important, especially
as in the case of autoimmune disorders the applied daily doses
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are relatively high [2, 3]. In transplantation surgery the mean
therapeutic doses have decreased in the recent years to reduce
toxic effects without losing immunosuppressive efficacy [1, 2].
Despite close monitoring of Cs trough levels, almost 50% of the
treated patients still suffer from serious renal [1—5] or neurolog-
ical [4, 6] side effects of Cs therapy. There is increasing
suspicion that Cs metabolites contribute to these undesirable
complications [4, 6, 71.
To properly address the renal pathological alterations occur-
ring during Cs treatment it is necessary to differentiate acute,
functional Cs effects and irreversible kidney lesion after long-
term therapy. Acute reduction of glomerular filtration rate
(GFR) is a constant feature in all patients undergoing Cs
therapy [1, 8, 9]. Although it is generally accepted that a
primary vasoconstriction of afferent arterioles is associated
with Cs application [1, 8, 91 there are sporadic investigations
measuring a more pronounced increase in efferent arteriolar
resistence [10]. The vasoconstrictive mechanisms underlying
the Cs action are currently under discussion; a general sympa-
thetic neural activation involving renal vessels was indicated by
an earlier study in rats [11] and was recently supported by data
from heart transplant patients [12]. Speculatively an influence
of Cs on the gene expression of local humoral regulators of
vasoactive compounds in endothelial or mesangial cells has
been proposed [1]. However the most favored hypothesis,
based on several experimental models [10, 13—17] and recent in
vivo findings [18, 19], suggests a local imbalance of vasoactive
substances, like platelet activating factor, prostaglandin E,
prostacyclin and thromboxane, endothelin or angiotensin II.
Cell culture experiments showing an enhancement of vasocon-
strictor induced rise of intracellular calcium in MC or smooth
muscle cells by Cs are in agreement with these investigations
[20—23]. Unlike these reversible functional changes, during Cs
therapy long-term treatment resulted in certain morphological
lesions [21 in primarily unaffected kidneys [5]. These investiga-
tions revealed the following main alterations: tubulointerstitial
damage, obliterative arteriolopathy, ischemic collapse (6 to
56%) or sclerosis of glomeruli (4 to 34%) associated with a
significant enlargement of the remnant glomeruli and an expan-
sion of the mesangial matrix. These toxic lesions, linked to Cs
therapy, and finally leading to a decline in the number of
functional glomeruli, are rarely reversible and potentially pro-
gressive [5]. A similar outcome of long-term Cs therapy was
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also considered in patients with autoimmune disorders receiv-
ing high Cs doses [3]. Cs effects on proximal tubular cells have
been observed independently from a reduced GFR [1, 8], and
might possibly be due to a generation of toxic metabolites by
the tubular cell cytochrome P-450 system [1] or a direct effect of
Cs on mitochondria of these cells [81.
Beside tubular, endothelial and vascular smooth muscle cells,
glomerular mesangial cells (MC) exhibit several properties
which could possibly link some of the functional and histolo-
gical changes observed in the kidney to distinct cellular effects
of Cs. As is also available for other kidney cell types, there are
several recent investigations supporting MC involvement in Cs
nephrotoxicity: Cs suppressed mesangial cell proliferation in
vitro, while non-immunosuppressive Cs analogues were with-
out effect [24]. Cs increased intracellular calcium and was
responsible for an enhanced MC sensitivity to vasoconstrictors
[9, 20—22]. Additionally, Cs induced platelet activating factor in
MC, which in turn caused contraction of MC and whole
glomeruli [10, 161. Cs changed the pattern of prostanoid pro-
duction towards vasoconstrictive compounds decreasing pros-
taglandin E2 [17] and increasing thromboxane A2 formation [1].
In vivo evidence supporting the pathophysiological role of the
mesangial cell includes the generation of reactive oxygen spe-
cies after Cs treatment [25], as MC are the main producers of
reactive oxygen of the non-inflamed glomeruli [26]. Further-
more, MC proved to be more sensitive to Cs and its metabolites
than murine lung and renal epithelial cells [27].
Cs metabolites are not easy to obtain, and to our knowledge
only two in vitro studies have evaluated single Cs metabolite
effects on tissue cells [20, 27]. On the other hand, an increasing
number of investigators have described toxic Cs side effects
associated with high metabolite levels [4, 6, 7]. Remarkably, in
these studies a normal trough level of the parent drug Cs has
been measured in the blood of patients.
Thus, the in vivo situation is complex and demands proper
evaluation of the activities of metabolite combinations 16, 7,
28—30], especially as the only studies done so far with Cs
metabolite combinations have shown synergistic immunosup-
pressive effects [28, 301. In our Department 29 distinct metab-
olites have been detected in bile of liver grafted patients, and in
addition to the 12 previously described metabolites the remain-
ing 17 new metabolites have been structurally analyzed by
FAB-MS [311. Thus, patients have to deal not only with the
presence of a few metabolites but with a combination of almost
thirty Cs degradation products [28—32]. So far, nothing is known
about the activities of secondary Cs metabolites on normal
tissue cells and no information is available about the interac-
tions of metabolite combinations.
In our initial experimental approach we have measured the
inhibition of rat glomerular mesangial cell proliferation as a
parameter for overall Cs metabolite activity. This proved to be
a sensitive in vitro model system providing initial data, which
might lead to more detailed studies of in vivo relevant end-
points of Cs metabolite actions like, for example, MC prosta-
glandin production or smooth muscle cell contractility. We
have employed 10 HPLC-purified, 'H NMR and/or FAB-MS
characterized Cs metabolites from bile of liver graft recipients
to determine the effects of single metabolites alone. Addition-
ally, and more important for the in vivo situation, we have
investigated the effects of metabolite combinations.
Methods
Materials
Cyclosporine (Cs) was a gift of Sandoz, Basle, Switzerland.
The stock solution of 2 mg/mI was kept at —20°C in dimethyl-
sulfoxide (DMSO). Reference Cs metabolites for the HPLC
purification method (Ml, M8, Ml3, Ml7, M18, M21, M26 and
M203-218) were donated by Dr. G. Maurer (Sandoz). In a
further collaboration with Dr. B. Ryffel, (Sandoz) we were
supplied with chemically synthetized metabolites (Ml7, M18,
M2 1, M203-2 18) in milligram amounts, which allowed us to
perform control experiments under similar conditions as de-
scribed below for the HPLC-purified metabolites prepared from
human bile.
All cell culture reagents were from GIBCO (Wiesbaden,
FRG), if not otherwise stated. The sources of the antisera for
immunocytochemical characterization of MC were: myosin
(rabbit anti-chicken) from R.B. Sterzel (Erlangen, FRG); fi-
bronectin (MoAb anti-human), vimentin (MoAb anti-human),
desmin (MoAb anti-human), and collagen type IV (MoAb
anti-human) from ICN (Eschwege, FRG); cytokeratin (MoAb
anti-cytokeratin-pan) from Boehringer (Mannheim, FRG); fac-
tor VIII (rabbit anti-human FITC conjugate) was a gift of Dr. F.
Drenk (Dept. of Clinical Immunology, Medical School Han-
foyer, FRG).
Preparation of cyclosporine metabolites
Cs metabolites were purified from human bile, which was
obtained from liver grafted patients usually receiving 2 mg/kg
Cs twice daily. For surgical reasons their bile was collected
through a T-drain placed in the bile duct. The obtained bile was
prepared according to our recently described extraction proce-
dure [321 with the following modifications. In brief, 500 ml
human bile were extracted by 500 ml dichloromethane. The
dichloromethane phase containing cyclosporine and its metab-
olites was evaporated and the residue was dissolved in 150 ml
acetonitrile/water pH 3.0 = 50/50 vol/vol. The sample was then
cleaned by adding 300 ml hexane and was extracted from the
aqueous phase by 150 ml dichloromethane. Dichloromethane
was evaporated, the residue dissolved in 2 ml acetonitrile/water
pH 3.0 = 50/50 vol/vol. cleaned by 4 ml hexane and 250 p1 were
injected into the HPLC system. The metabolites were eluted
from preparative columns (3 serially linked 250 x 10 mm
columns filled with 10 m, 100 A, RP8 material) by a concave
gradient as described before [31, 32]. Fractions were manually
collected and stored in acetonitrile/water (pH 3.0 50/50
vol/vol at 4°C).
Since the Consensus Conference in Hawk's Cay, USA, in
June of 1990 [33]; a new cyclosporine metabolite nomenclature
has been introduced. However, for convenience we used the
established nomenclature previously proposed by Maurer et al
[34] and Christians et a! [32] (indication of metabolites by the
H-labeled numbers for metabolites as recently defined by our
group). To permit a comparison with the new "Consensus
Nomenclature," the following is a brief translation (old = new):
Ml = M9; M8 = M19; M13 = M4N9; M17 = Ml; M18 = Mic;
M21 = M4N, M25 = M14N; M26 = M1c9; M203-218 M1A.
The new nomenclature describes metabolic alterations of the 11
amino acids of Cs by special suffices following the amino acid
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number: no suffix = hydroxylation; N = N-desmethylation; c =
cyclization; A = oxidation to an acid.
Mesangial cell culture
MC were prepared from Sprague-Dawley rat kidneys as
described [24]. The cells were characterized by immunofluores-
cence showing a positive reaction with myosin, vimentin,
fibronectin, desmin and collagen type IV, and negative reaction
with keratin and factor VIII antisera.
The culture medium used for the experiments consisted of
DMEM, supplemented with 2 mmol/liter glutamine, 100 U/mi
penicillin, 100 g!ml streptomycin, 1% non-essential amino
acids and 5% fetal calf serum (Gibco). MC cultures routinely
proved to be negative for mycoplasma contamination by DAPI
staining (4'6-diamino-2-phenylindole; Sigma, Deisenhofen,
FRG).
Determination of cyclosporine metabolite activity
MC were seeded in 96-well flat bottom plates (Nunc, Wies-
baden, FRG) at a density of 5000 cells/well in culture medium
and incubated in humidified atmosphere for 24 hours at 37°C in
5% CO2. The HPLC purified, highly concentrated metabolites
(300 to 600 tg of the respective metabolite per experimental
series) dissolved in acetonitrile were dried in glass vials with
nitrogen immediately before starting the assay. To increase the
recovery the individual glass vials were washed three times
with a respective volume of 5 p1 DMSO (centrifugation at
12,000 g). Subsequently the vials were rinsed three times with
1.5 ml culture medium (5% fetal calf serum) to give the stock
solutions for the serial dilutions. Similarly, the chemically
synthesized metabolites for control experiments were dissolved
first in DMSO and then in medium. The highest concentration
of the metabolite dilutions applied to the MC contained not
more than 0.16% DMSO. Mter 24 hours when MC were
subconfluent either Cs, metabolites alone, metabolite combina-
tions, medium or DMSO controls were added to a final volume
of 200 jd/well. The cells were further incubated for 48 hours,
and after adding 0.5 Ci [3H]-thymidine for a further 24 hour
period. The incubations were stopped by deep freezing, and
then the thawed and sonified plates were harvested with an
automatic cell harvester (Titertek). Radioactivity was deter-
mined by liquid scintillation counting.
The precise concentrations of the serial dilutions of Cs and Cs
metabolites used were checked by HPLC in parallel to the
respective incubation time. This became necessary as the
recovery of purified (but also of chemically synthesized) metab-
olites in the final DMSO/medium solution varied considerably.
The final concentrations of the metabolites shown throughout
this paper were based on these parallel HPLC measurements.
To test the possibility that MC themselves were able to
metabolize Cs we incubated MC in culture flasks (l0 MC/flask)
under identical medium conditions with 0.4 mg/liter native Cs
for 72 hours. The incubation was stopped by adding acetonitrile
to the separated supernatant and MC cell fraction. The samples
were treated as described by Christians et al [32].
Determination of reversibility and cytotoxicity
The reversibility of Cs metabolite effects was determined by
first incubating a duplicate set of MC with metabolites alone or
in combination as described before. After 72 hours one-half of
the metabolite treated MC was washed three times during a six
hour period with culture medium containing 5% FCS, 37°C.
Each washing step was preceded by a short centrifugation step
of the microtiter plates (300 x g, 3 mm) to avoid loss of cells.
Subsequently, both the washed and the control cells, still
exposed to the initial metabolite dilutions, were incubated for
another 48 hours. Then both MC fractions were pulsed for 24
hours with [3H]-thymidine and proliferation was determined as
described before.
For cytotoxicity assays MC at a density of 5 x l0 cells/well
were grown in culture medium in 96-well plates overnight. After
addition of serial Cs metabolite dilutions in fresh medium and
another 24 hours incubation time the microtiter plates were
centrifuged (300 X g, 5 mm) and the supernatant decanted. A
1/400 solution of neutral red dye in complete culture medium
was added (150 p1/well) and living MC were allowed to incor-
porate the dye during an additional hour of incubation at 37°C,
5% CO. MC were washed twice with ice-cold PBS and cell
incorporated neutral red dye was solubilized by the addition of
150 p1/well Sorensen-buffer and shaking of the microtiter plates.
The neutral red absorption was determined at 540 nm in an
ELISA reader.
Statistics
Each data point of Cs and single metabolite activities repre-
sents the mean of six determinations. In Figure 1 A and B the
data points shown were raised in four (+ one for HPLC purified
Cs) and three completely independent experiments, respec-
tively: bile from different patients, separate HPLC extraction
procedures, as well as separate performances of HPLC runs to
assess the final metabolite concentrations. Concentration re-
sponse curves calculated with the best curve fit are depicted. In
all the remaining figures the data points represent the mean
standard deviation (SD) of three independent experiments (6
determinations per experiment, respectively). For clarity the SD
of the mean values in Figures 1, 2 and 3 have been ommitted.
The mean standard deviation throughout this experimental
series (N> 500) was 9.80 4.47%.
Results
The metabolite concentrations depicted throughout the fol-
lowing figures refer to the actual concentrations measured by
HPLC in the dilution medium. HPLC assessment in parallel to
the respective experiment reconfirmed the purity of the human
bile-derived metabolites and excluded alterations caused by
DMSO or culture medium (data not shown). Moreover, control
experiments with newly synthesized metabolites (Ml7, M18,
M21, M203-2l8) were performed in addition to the studies on
purified metabolites. The results revealed an identical activity
of these synthesized preparations either alone or in combina-
tion, provided their respective concentration in the serial dilu-
tions was measured by HPLC in parallel to the MC proliferation
assay (data not shown). DMSO controls (0.16%, voL/vol) cor-
responding to the highest concentration reached with metabo-
lites alone or with combinations caused a growth reduction by
6.64 2.03 % (mean SD, N> 100) compared to medium
controls.
In additional, preceeding experiments MC cultured in flasks
were incubated with a concentration of 0.4 mg/liter native Cs
for 72 hours. We determined that MC under these assay
conditions were not able to generate Cs metabolites (data not
shown). The effect of Cs and metabolites on mesangial cell
{3H]-thymidine incorporation was dependent on cell density,
that is, confluent, contact-inhibited MC were less sensitive
(data not shown). Nevertheless, the relative activity of the
metabolites was retained.
Effect of single cyclosporine metabolites
Native Cs caused a significant, concentration dependent
decrease of MC proliferation starting at 0.1 mg/liter with a 50%
antiproliferative action (IC50) at a dose of 1.25 mg/liter (Fig. 1A,
Table 1). Cs purified from human bile extracted as described
resulted in a comparable growth inhibition curve.
Testing the metabolite activity revealed two separate groups
of metabolites, the "active" metabolites Ml, M8, M17, M18,
M21, M26, (Fig. 1 B and C) and the relatively "inactive",
secondary metabolites M13, M25, M203-218, H355 (Fig. 1D).
Figure lB shows the concentration dependent effects of meta-
bolites Ml and M8 from three independent experiments. Rep-
resentative for this study, these data confirmed that the antipro-
liferative effects of the metabolites were not significantly
influenced by bile from patients, metabolite preparation proce-
dure, MC cultivation or by HPLC re-assessments, because all
of these parameters were different in these three experiments.
Figure 1C summarizes the activities of additional four active
metabolites M17, M18, M21, M26, revealing that metabolite
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Fig. 1. Antiproliferative effects of Cs and single metabolires. The ordinate gives the percent of proliferation of MC at the respective metabolite
concentration compared with control. Best regression curve fits were calculated: A. MC were incubated for 72 hours with native Cs (•) and
HPLC-purified Cs (0) from human bile. Data points depicted represent the mean of six determinations, B. The activities of the metabolites Ml
(0) and M8 (•) were determined in three independent experiments: bile from different patients, independent HPLC-purification procedures and
HPLC-reassessments of the actual concentrations and different MC incubations. C. Antiproliferative effects of the metabolites M17 (D), M18 (A),
M21 (•), M26 (V). Data points represent the average of three independent assays with six determinations, respectively. D. The activity of the
secondary metabolites M13 (0), M25 (A), M203-218 (•), H355 (7) was determined as described in C.
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Table 1. Summary of metabolite concentrations (mg/liter) resulting in 50% inhibition of proliferation (IC50) of Sprague-Dawley rat mesangial
cells compared with the chemical structure of the metabolites
IC50
Structure
AA9 AA1
R R1
AA3
—
R2
Other
modifications
Cyclosporine 1.25 H CH3 CH3
Active metabolites
21 (H430), 1 6.0 H CH3 H
18 (H400), 1 9.0 H CH2 OH CH3 AAI cyclizat.
26 (H270), 2 10.5 OH CH2 OH CH3 AAI cyclizat.
I (H390), 1 10.8 OH CH3 CH3
8 (H250), 2 10.8 OH CH2 OH CH3
17 (H370), 1 12.5 H CH2 OH CH3
Inactive metabolites
13 (H320), 2 >20.0 hydroxylation/N-demethylation
25 (H300), 2 >25.0 H CH2 OH H
203-218 (H350), 2 >50.0 H COOH CH3
(H355), 2 >50.0 hydroxylated (not at AA9) M17
For assay conditions see Methods.
The amino acid (AA) residues (R) are numbered as shown in Figure 7. The nomenclature of the metabolites proposed by Maurer et al [34] and
in brackets according to Christians et al [321 was used. Identification as primary (1) or secondary (2) metabolites refers to studies of the
metabolization pathways of Cs (Fig. 7) by Sewing et al [311.
M2 1 had the highest antiproliferative potency on rat MC with an
IC50 of 6.0 mg/liter. The secondary metabolites M13, M25,
M203-218 and H355 had an IC50> 20 or 25 mg/liter as shown in
Figure 1D. The 1C50's of CS and the 10 metabolites tested on rat
MC are summarized and compared to the their chemical struc-
ture in Table 1.
Effect of metabolite combinations
To get informations concerning the interaction of Cs metab-
olites on rat MC we tested the growth inhibitory action of
several combinations of two, three or four metabolites. Figure
2 demonstrates the concentration dependent effects of the
metabolite combinations Ml + M17 (Fig. 2A) and M203-218 +
H355 (Fig. 2C), respectively. Whereas the combination of
metabolites Ml + M17 produced an additive effect summarizing
the growth inhibition of each metabolite alone (Fig. 2A),
combination of the secondary metabolites M203-218 + H355
resulted in a significant synergism (Fig. 2C).
Combinations of three metabolites, triple combinations (Fig.
2), resulted in an additive antiproliferative effect of the metab-
olites Ml + M17 + M18 (Fig. 2B), but when metabolites
M203-218, H355 and M2l were combined we found a synergis-
tic activity (Fig. 2D). In the experiments employing the second-
ary metabolites M203-218 and H355 the synergism of both the
double (Fig. 2C) and the triple combination (Fig. 2D) was more
pronounced at low metabolite concentrations. The phenome-
non that a combination of active metabolites reached not more
than additive antiproliferative effects, whereas combined inac-
tive metabolites led to synergism, was also observed in further
experiments using the double metabolite combination Ml +
M18 (additive) or the triple metabolite combinations Ml +M8
+ M17 (additive) and M13 + M203-2l8 + H355 (synergistic)
(data not shown).
A combination of four different metabolites (Fig. 2E) caused
a remarkable growth inhibition of MC already at low concen-
trations of the participating metabolites. The antiproliferative
effect of this quadruple combination was additive for the
concentration range tested.
Influence of native cyclosporine on metabolite combinations
To test the antiproliferative effect of Cs together with metab-
olite combinations on rat MC we used a concentration of 0.625
mg/liter Cs. Cs alone at this concentration produced a growth
inhibition of 30% (Fig. 3), which was expected from the
concentration response curves (Fig. 1). The combination of the
metabolites Ml + M17 + M18 (Fig. 3A, upper curve) or the
metabolites M2l + M203-218 + H355 (Fig. 3B, upper curve)
resulted in the described additive or slightly synergistic antipro-
liferative activities, respectively. Combining native Cs (0.625
mg/liter) with the triple metabolite mixture did not significantly
enhance the growth inhibition in response to either Cs or the
metabolite combinations (Fig. 3 A and B, lower curves). The
effects seemed to be independent from each other.
Reversibility of Cs metabolite effects
To exclude the possibility of direct and nonspecific toxic
effects of purified or synthesized Cs metabolites, we tested both
the reversibility of the antiproliferative metabolite action after
72 hours and the effects of Cs metabolites on MC viability after
24 hours measured by neutral red staining. Figure 4 demon-
strates that a washing procedure with FCS-containing medium
after 72 hours incubation with single metabolites (Fig. 4A: M17;
B: M18; C: M21 and D: M203-218) and a subsequent addition of
fresh medium led to a full recovery of MC proliferation rate
compared to controls. As an exception the effect of the highly
lipophilic M21 (Fig. 4C) at the maximal concentration of 30.2
mg/liter was only partially reversed. Similarly, the growth rate
of MC treated with triple (Fig. 5A: M17 + M21 + M203-218) or
with quadruple combinations (Fig. SB: M17 + M18 + M21 +
M203-218) returned to control levels after 72 hours of metabo-
lite-free incubation. Providing further evidence for an antipro-
liferative activity rather than a direct cytotoxicity of Cs metab-
olites, Figure 6 demonstrates the results of a living cell stain
with neutral red dye of MC incubated for 24 hours with
increasing concentrations of Cs metabolites. Neither single
metabolites (Fig. 6A) nor triple and quadruple combinations
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(Fig. 6B) caused a direct mesangiolysis. As a control we
determined that even an excessively high concentration of the
parent drug cyclosporine of 50 mg/liter only led to a lysis of 33.8
2.9% of MC under these conditions.
Discussion
The aim of this investigation was to determine potentially
toxic effects of a representative group of Cs metabolites from
human sources in an in vitro system. We could demonstrate
that combinations of Cs metabolites had clearly additive growth
inhibitory effects on rat glomerular MC. Moreover, combina-
tions of inactive metabolites acted synergistically.
As previously outlined measuring MC [3H]-thymidine incor-
poration has to be taken as a simple, initial experimental setting
to get informations about Cs metabolite effects on a renal,
smooth muscle-like cell type. Using subconfluent MC being in
the logarithmic proliferation phase provided us with a sensitive
system to test Cs metabolite activities in a reasonable time.
Control experiments clearly distinguished these antiprolifera-
tive effects of both single metabolites and metabolite combina-
tions from unspecific mesangiolysis. The complete reversibility
and the lack of any direct lytic effect together with the chemical
structure related activities of single metabolites, discussed in
detail later, point towards a specific action of the individual Cs
metabolites and their combinations on rat MC. In this respect
the model system used might provide useful informations for
the analysis of other relevant target cell systems and their
products.
The basis of our investigations with metabolite combinations
was the evaluation of single metabolite effects. We used a
standardized HPLC-procedure of metabolite purification and
characterization from human bile [discussed in 31, 32], which
permitted generation of sufficient material for the experimental
series. Control experiments with small amounts of synthesized
metabolites (M17, M18, M2l, M203-218) revealed identical
results and confirmed the reliability of the metabolite prepara-
tion method using HPLC (data not shown). The activities of
metabolites either purified or synthesized were dependent on
the degree of metabolization when tested alone (Fig. 7, Table
1). The rank order is Cs ' M21, Ml8, M26, Ml, M8, Ml7
M13, M25, M203-218, H355. The group of active metabolites
included four primary metabolites (Ml, Ml7, M18, M21), which
are either hydroxylated or demethylated products of cy-
tochrome P450-dependent liver metabolization (Table 1). It is
noteworthy that metabolite M2 1, which according to its HPLC
elution time appeared to be closest in the lipophilic nature to
Cs, exhibited the highest activity in our assay system. Addi-
tionally, two secondary metabolites (M8, M26) showed an IC50
comparable with that of the primary metabolites. Both of the
latter metabolites have a chemical structure closely related to
primary metabolites, especially with respect to the biologically
important structure at amino acid residue 1 (AA1) [9]. M8 and
M26 share an additional hydroxylation at AA9. It is therefore
tempting to speculate that modifications at this part of the Cs
molecule have no biological significance [29]. The group of the
secondary metabolites (M13, M25, M203-218, H355) was tested
for the first time in this investigation. These compounds were
generated in vivo from primary metabolites by a further de-
methylation (M13, M25), oxidation (M203-218) or hydroxyla-
tion (H355) (Table 1). Taken together there seemed to be an
inverse relationship between structural changes along the met-
abolic pathways (Fig. 7) to more hydrophiic and polar com-
pounds and the antiproliferative activities on rat MC. The
concentrations we measured for single metabolites antiprolifer-
ative activities were in agreement with recent in vitro studies
[24, 271 and we would not expect nephrotoxic effects of single
metabolites (35) as the necessary high concentrations have not
been observed in vivo (36, Table 2).
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Fig. 3. Combinations of three metabolites with (A) or without (S) Cs. The antiproliferative effects of the combined metabolites Ml + M17 + M18
(A) and M2l + M203-218 + H355 (B) were tested on MC during a 72 hour incubation period without or with the addition of Cs at a concentration
of 0.625 mg/liter. The results are the mean of six determinations (SD below 10%) of a representative experiment.
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The second part of our experimental series was to investigate
the activities of metabolite combinations. As outlined previ-
ously, Cs treated patients have to deal with the presence of 29
different metabolites. In a first attempt to get closer to this in
vivo situation we tested different combinations of two, three (±
native Cs) or four metabolites. The only published investigation
using well defined metabolites, in which at least a combination
of two compounds was tested (Cs + M17), described a syner-
gistic immunosuppressive effect [30]. In addition, in a recent
paper Wallemacq et al [281, also testing the immunosuppressive
activities of HPLC-purified metabolites, have demonstrated a
possible synergistic" action of unidentified metabolites from a
more polar peak. In our own investigation on the immunosup-
pressive activities of Cs metabolites in a parallel experimental
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Fig. 4. Reversibility of single cyclosporine metabolite effects. Two parallel sets of subconfluent rat MC were incubated with serial dilutions of
single metabolites for 72 hours as described in Figure 1. One part of the samples was incubated without removing Cs metabolites for another 72
hour period (. The second identical set was washed three times with 5% FCS containing medium after the initial 72 hours, supplemented with
fresh metabolite-free medium and incubated for additional 72 hours (n). Except for M21 at 30.2 mg/liter (C) the proliferation rate of washed MC
returned back to control levels for all concentrations and metabolites tested (A: Ml 7; B: M 18; C: M2 1; D: M203-2 18). Results expressed as
percentage of control proliferation are the mean so of three separate experiments performed with sixfold determinations.
series with Sprague-Dawley lymphocytes (Radeke Ct a!, manu-
script in preparation) we also found slightly synergistic activi-
ties of Cs in combination with metabolite M17 or with metab-
olite M203-218. However, and this refers to the results
presented herein, the most prominent synergistic effects were
observed, when we used secondary metabolites like M203-2l8
and H355 in combination. On rat MC these compounds gener-
ated in a second cycle of liver metabolization (Fig. 7), although
exhibiting very low activity when given alone, acted synergis-
tically or enhanced the activity of additionally present primary
metabolites (metabolite M21).
Combinations from the group of active metabolites led to
additive effects. But, obviously this might not be less important
in vivo, since the concentration of the individual metabolites,
which participated in the strong antiproliferative effects (for
example in the quadruple combination), were in the range of
metabolite concentrations measured in vivo [34] (Table 2).
Table 2 summarizes trough blood and urine metabolite levels
of three different groups of Cs treated patients. These data
reveal that the urine concentrations exceeded the blood trough
levels and that the ratio of urine to blood concentration further
increased with enhanced impairment of liver function. Support-
ing these measurements from our own laboratory, Rosano et al
measured much higher tissue concentrations of Cs, metabolite
Ml and Ml7, especially in the renal cortex compared to blood
concentrations [36]. If we sum up the effects of the urine
concentrations of the metabolites (without native Cs effect)
occurring in group III (Table 2, liver allograft patients) the
results in our in vitro system would be a 50% inhibition of MC
growth. It has to be mentioned that the concentrations mea-
0
00
00C
1)C0
E
sured in patients' blood and urine represent trough levels and
these are the baseline levels occurring during Cs therapy. In
addition only ten metabolites would be sufficient to cause a 50%
reduction of MC proliferation, whereas thirty metabolites are
present in the vicinity of human MC in vivo. Ryffel [37] showed
that Sprague-Dawley is the most insensitive rat strain, which
increases the evidence that by analogy these concentrations
might also be relevant for human glomerular MC.
While native Cs alone was relatively active on MC, we
observed no significant additive action of Cs in combination
with different metabolites. The reasons for this discrepancy
compared with the combined metabolite activities are not
known. In mesangial cells Cs has been shown to act on the cell
membrane level to increase the availability of intracellular
calcium. This leads to increased responses to vasoconstrictors
[20, 21]. On the other hand, the nuclear actions of Cs on
transcription regulator genes are known to be most important
for the immunosuppressive activity [1, 381. However, Fahr,
Hiestand and Ryffel [291 have recently examined the immuno-
logical effects of Cs and several metabolites in comparison with
their binding affinity to cyclophilin. Interestingly, although both
M17 and M21 had a comparable high activity at inhibiting
interleukin 2 mRNA expression of human lymphocytes and at
suppressing mixed lymphocyte reaction in a mouse system,
only M17 showed relevant binding affinity to cyclophilin. Thus,
even in typical target cells for Cs metabolite actions there was
no clear association at this level which suggested different
pathways leading to the final effect. Similarly in MC different
cellular target systems might exist for either Cs and/or its
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Fig. 5. Reversibility of the MC growth inhibitory effects of Cs metabolite combinations. As described for single metabolites (Fig. 4) three washing
cycles with 5% FCS containing medium after an initial incubation period of 72 hours led to a complete reversibility of the concentration dependent
inhibition of MC growth by triple (A) or quadruple combinations (B) after an additional 72 hour incubation time. Symbols are: (U) 3H-thymidine
incorporation in the presence of triple or quadruple combinations; () 3H-thymidine incorporation after three washing cycles. The means SD
of three experiments with sixfold determinations are depicted as percentage of control.
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Table 2. Cs and metabolite trough levels (pg/liter, mean SaM) in blood and urine of kidney and liver allograft patients
Metabolites
Group I Group II Group III
Blood Urine Blood Urine Blood Urine
Cyclosporine
21(11430)
135 9
5 4
329 41
85 13
159 19
34 19
406 74
81 16
175 26
5 4
467 105
85 13
18 (11400) 10 5 412 74 37 31 891 451 14 5 587 130
26 (H270) I 1 255 51 10 8 736 340 18 6 1,490 308
1 (11390) 73 7 262 32 159 81 497 205 53 14 593 116
8 (11250) 32 4 162 36 123 52 616 275 152 29 2,260 522
17(11370) 180 12 877 106 232 38 1,464 434 157 27 1,668 327
13 (11320) 4 2 48 10 — 115 42 21 6 689 14
25 (H300) 3 2 32 11 — 118 70 3 2 582 141
203-218 (11350) 12 4 29 7 40 13 228 94 22 6 1,378 306
(11355) — 4±2 — 21±9 — 4±2
Data were adapted from an investigation of BLECK JS, SCHLITT Hi, CHRISTIANS U, SCFIOTTMANN R, THIESEMANN C, STROHMEYER S.
KOHLHAW K, WONIGEIT K, PICHLMAYR R, SEWING K-F: Kidney and liver function dependent change of cyclosporine metabolite pattern in blood
and urine in kidney grafted patients (manuscript in press) and [321, respectively, and measured with the equipment described in the method section.
Nomenclature of the metabolites is described in Table 1. Group 1 consisted of 19 kidney graft patients with normal liver function, group II of 8
kidney graft patients with cholestasis and group III of 18 liver graft patients. None of the patients received additional medication known to interfere
with metabolization and/or elimination of the daily cyclosporine dose of 2.0 1.3 mg/kg body wt or 2.9 1.2 mg/kg body wt of the kidney or liver
graft patients, respectively.
rnetabolites. Nevertheless, in our experiments the combina-
tions of metabolites still had antiproliferative effects on MC in
the presence of Cs. These in vitro results are in agreement with
observations in patients who suffered from severe complica-
tions which were independent of Cs trough levels 114, 6, 341.
Finally, we conclude that: 1) concentration dependent effects
of single metabolites on rat MC were observed. The activities
were correlated to the degree of metabolization. 2) The com-
bined addition of two, three or four metabolites to target cells
resulted in additional antiprolilerative effects of the active
metabolites (Ml, M8, Ml7, Ml8, M21, M26). This might be
relevant in vivo, since the concentrations of the respective
metabolites contributing to the overall effect were measured in
urine of Cs treated patients. 3) Moreover, secondary metabo-
lites with a higher degree of metabolic alteration, although
exhibiting low activity when given alone, showed synergistic
growth inhibiting effects on rat MC. Chronic toxicity of Cs
therapy is a major problem and more detailed studies using
metabolite combinations may help to develop strategies to
decrease undesired effects.
B
0.80
0.60
0.40
0.20
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Fig. 6. Cytotoxic effects of single Cs metabolites (A) (0, M17;•, M18; A, M21; A, M203-218) or inetabolite combinations (B) (Symbols are: 0,
combination M17 + M21 + M203-218; •, combination M17 + M18 + M21 + M203-218) on rat MC. Five times l0 confluent MC/well in microtiter
plates were incubated with the respective metabolite concentrations for 24 hours, washed and viable MC stained with neutral red dye for one hour.
The absorption at 540 nm was determined in an ELISA-reader after the solubilization of the dye with Sorensen-buffer. The results are derived from
one representative out of a series of three comparable experiments and expressed as mean Sn of triplicates.
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Fig. 7. Metabolization pathway of cyclosporine adopted from [31]. The cyclosporine formula is skeleted to the cyclic structure and its
metabolization sites. The numbers in the metabolite formulas correspond to the numbers in Tables 1 and 2, and use the nomenclature of Maurer
et a! [34] and Christians et a! [32].
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